# US 2026/0077029 A1 · Immunogenic Compositions of PEGylated Polysaccharide Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077029 A1
- Document ID: US20260077029A1
- Status: Published application
- Kind: A1
- Application number: 19/334,570
- Filed: 2025-09-19
- Published: 2026-03-19
- Earliest claimed: 2024-09-19
- Assignees: Inventprise, LLC
- Applicants: Inventprise, Inc.
- Inventors: Subhash V. Kapre; Anup K. Datta
- Web page: https://patentgrep.com/patent/US20260077029A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to complexes comprising multivalent compounds, immunogenic compositions, and vaccines comprising carrier protein coupled to pegylated bacterial capsular polysaccharides and uses thereof. In particular, compositions of the invention comprise bacterial capsular conjugated to polyethylene glycol (PEG) and like compounds to which are couple linkers and/or carrier proteins. PEGylated polysaccharides are derived from many different bacterial serotypes such as Streptococcus pneumoniae. The carrier protein may be coupled to the pegylated polysaccharide through homo or hetero mono-functional, bi-functional, and/or multi-functional linkers.

## Claims

### Claim 1

A multivalent immunogenic complex comprising bacterial capsular polysaccharides conjugated to polyethylene glycol.

### Claim 2 (depends on 1)

The complex of claim 1, wherein the multivalency comprises 25 or more different polysaccharides (PSs), 35 or more different PSs, 45 or more different PSs, 55 or more different PSs, 65 or more different PSs, 75 or more different PSs, or 85 or more different PSs.

### Claim 3 (depends on 1)

The complex of claim 1, wherein the bacterial capsular polysaccharides comprise multiple serotypes of S. pneumoniae.

### Claim 4 (depends on 1)

The complex of claim 1, wherein the bacterial capsular polysaccharides are derived from S. pneumoniae.

### Claim 5 (depends on 4)

The complex of claim 4, wherein the bacterial capsular polysaccharides of S. pneumoniae comprise serotypes 1, 2, 3,4, 5, 6A, 6B, 6C, 6D,7F, 8, 9V, 9N, 9A, 9B, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B.

### Claim 6 (depends on 1)

The complex of claim 1, wherein the capsular polysaccharides have a molecule weight of from about 10 kDa to about 300 KDa.

### Claim 7 (depends on 1)

The complex of claim 1, wherein the polyethylene glycol has a molecule weight of from about 1 kDa to about 50 KDa.

### Claim 8 (depends on 1)

The complex of claim 1, which is associated with a carrier molecule.

### Claim 9 (depends on 8)

The complex of claim 8, wherein association is via covalent coupling.

### Claim 10 (depends on 8)

The complex of claim 8, wherein the carrier molecule comprises a protein.

### Claim 11 (depends on 10)

The complex of claim 10, wherein the protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), Nisceria meningitidis protein PorB, RSV virus proteins, Bordetella pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.

### Claim 12 (depends on 1)

The complex of claim 1, which comprises 4 micrograms or less of total polysaccharides per dose.

### Claim 13 (depends on 8)

The complex of claim 8, which comprises from about 0.5% to about 0.7% by weight of bacterial capsular polysaccharide and carrier molecule per dose.

### Claim 14 (depends on 8)

The complex of claim 8, which comprises about equal amount by weight of capsular polysaccharides to total carrier molecule.

### Claim 15 (depends on 8)

The complex of claim 8, which comprises a greater amount by weight of capsular polysaccharides to total carrier molecule.

### Claim 16 (depends on 1)

The complex of claim 1, further comprising of at least one adjuvant.

### Claim 17 (depends on 16)

The complex of claim 16, wherein the adjuvant is selected from the group consisting of aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, a TLR7/8 agonist, and combinations thereof.

### Claim 18 (depends on 17)

The complex of claim 17, wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and/or aluminum hydroxide.

### Claim 19 (depends on 1)

The complex of claim 1, comprising one or more serotypes of S. pneumoniae, H. influenza type a or b; S. pneumoniae, Group B Streptococcus, N. meningitis or combinations thereof.

### Claim 20 (depends on 1)

The complex of claim 1, wherein the capsular polysaccharides are derived from S. pneumoniae, Group B Streptococcus serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, IX, or N, Haemophilus influenzae serotypes a/b/c/d/e/f, non-typeable Haemophilus influenzae (NTHi), Moraxella catarrhalis Lipooligosaccharides(LOS), N. meningitis serotypes A, B, C, Y, W-135 or X, or combinations thereof.

### Claim 21 (depends on 1)

The complex of claim 1, which, upon administration to a subject, generates a lower immune response to carrier protein in comparison to monovalent conjugates comprised of the same capsular polysaccharides.

### Claim 22 (depends on 1)

The complex of claim 1, which provides effective treatment or prevention of infection by Gram-positive and/or Gram-negative bacteria.

### Claim 23 (depends on 1)

The complex of claim 1, further comprising a therapeutically effective amount and a pharmacologically acceptable carrier.

### Claim 24

The method for manufacture of complexes of PEGylated polysaccharides comprising:
conjugating PEG to multiple bacterial polysaccharides forming PEGylated polysaccharides;
activating the PEGylated polysaccharides;
coupling spacer/linker molecules to the activated PEGylated polysaccharides, wherein the linker/spacer is about 2.0 Å to about 40 Å; and
coupling activated PEGylated polysaccharide to carrier proteins forming complexes.

### Claim 25

The method for manufacture of a complex of PEGylated polysaccharides comprising:
activating carrier proteins to form activated carrier proteins;
reducing a disulfide of each carrier protein to create a sulfhydryl group; and
coupling PEGylated polysaccharides to the activated carrier proteins forming the complex.

### Claim 26 (depends on 25)

The method of claim 25, wherein the activated carrier proteins are selected from the group consisting of cross-reactive material (CRM197) obtained or derived from C. diptheriae, and recombinant CRM197 obtained or derived from P. fluorescens or E. coli.
